Experimental infusion aims to restore ovarian function in young women with early menopause
NCT ID NCT05494723
First seen Dec 31, 2025 · Last updated May 23, 2026 · Updated 20 times
Summary
This early-stage study tests the safety of a new drug called YB-1113 for women under 40 with premature ovarian insufficiency (POI), a condition that causes early menopause and infertility. Six participants will receive the drug through an IV infusion. Researchers will monitor side effects and measure hormone levels to see if ovarian function improves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POI are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.